

Hey everybody! Ya girl u/articzone is back for another DD on the top 5 most mentioned stocks in this sub. Below you will see the table with a few non-penny stocks that have been mentioned here, I will not be doing the DD on them.

Definitions:

Golden cross - This occurs when a 50-day short-term moving average crosses over a 200-day long-term moving average. Analysts and traders use this as signaling a definitive upward turn in a market. Basically, the short-term average trends up faster than the long-term average, until they cross.

Blockchain - A blockchain is a type of database. A blockchain is a system people use to communicate information without using a server. This is the value of a blockchain. Blockchain builds on the idea of P2P networks and provides a universal data set that every user can trust, even though they might not know or trust each other.

Hash power- is the power that your computer or hardware uses to run and solve different hashing algorithms. These algorithms are used for generating new cryptocurrencies and allowing transactions between them. This process is also called mining.

Ticker	Company Name	u/articzone		Current Price	\$ Change From Last Close	Previous Close	% Change	52 Week High	52 Week Low	Percent from 52 Week High	Percent from 52 Week Low	Market Cap	Volume in shares	Float	Total Shares Issued
		Mentions	90 Day Chart												
ASRT	Assertio Holdings Inc	200		\$0.85	-\$0.10	\$0.95	-10.21%	\$1.45	\$0.33	-41.38%	157.58%	140.6M	11,375,849	1.71%	170.9M
AMC	AMC Entertainment Holdings Inc	129		\$8.01	-\$0.28	\$8.29	-3.38%	\$20.36	\$1.91	-60.66%	319.37%	2.7B	137,028,038	16.91%	377.8M
CTXR	Citius Pharmaceuticals Inc	125		\$2.03	-\$0.03	\$2.06	-1.46%	\$2.90	\$0.42	-30.00%	383.33%	255.3M	14,643,074	4.47%	125.8M
SOS	Sos Ltd - ADR	89		\$4.77	-\$1.27	\$6.04	-21.03%	\$15.88	\$0.51	-69.96%	835.29%	550.7M	137,103,316	0.00%	121.5M
AGTC	Applied Genetic Technologies Corp	61		\$5.08	-\$0.22	\$5.30	-4.15%	\$9.67	\$2.29	-47.47%	121.83%	216.7M	1,912,830	3.82%	42.7M
TRCH	Torchlight Energy Resources Inc	50		\$2.48	\$0.05	\$2.43	2.06%	\$4.83	\$0.21	-48.65%	1080.95%	353.7M	23,371,106	6.99%	142.6M
OBSV	Obseva SA	38		\$3.90	\$0.01	\$3.89	0.26%	\$6.30	\$1.63	-38.10%	139.26%	316.8M	3,117,262	4.24%	81.2M
NG	NovaGold Resources Inc.	24		\$8.35	-\$0.61	\$8.96	-6.81%	\$12.85	\$4.65	-35.02%	79.57%	2.8B	2,801,759	3.33%	331.3M
GHSI	Guardian Health Sciences	24		\$0.50	-\$0.19	\$0.69	-27%	\$1.40	\$0.17	-64.29%	194.12%	54.8M	74,074,941	4.61%	108.6M
ABEV	Ambev ADR Representing One Ord Shs	21		\$2.55	-\$0.07	\$2.62	-3%	\$3.40	\$1.90	-25.00%	34.21%	219.2B	38,830,781	0%	15.7B
SNDL	Sundial Growers Inc	20		\$1.33	-\$0.04	\$1.37	-3%	\$3.96	\$0.14	-66.41%	850.00%	2.1B	255,416,545	6.94%	1.6B
CTRM	Castor Maritime Inc	16		\$1.00	-\$0.01	\$1.01	-1%	\$2.60	\$0.11	-61.54%	809.09%	#N/A	78,352,692	6%	687.3M
VGZ	Vista Gold Corp.	14		\$0.93	-\$0.03	\$0.96	-3%	\$1.45	\$0.36	-35.86%	158.33%	95.2M	827,764	0.30%	102.7M
CIDM	Cinedigm Corp	13		\$1.40	-\$0.06	\$1.46	-4%	\$6.00	\$0.25	-76.67%	460.00%	232.3M	12,485,312	6%	166.0M
KTRA	Kintara Therapeutics Inc	13		\$2.13	\$0.15	\$1.98	8%	\$3.35	\$0.38	-36.42%	460.53%	65.2M	1,231,789	3.03%	30.6M
LRKO	Luokung Technology Corp	13		\$1.55	-\$0.26	\$1.81	-14%	\$3.86	\$0.34	-59.84%	355.88%	492.7M	17,631,950	0.63%	268.2M
GTE	Gran Tierra Energy Inc	13		\$0.85	-\$0.04	\$0.89	-5%	\$1.23	\$0.18	-30.89%	372.22%	402.0M	13,450,951	0.29%	367.0M
CSCW	Color Star Technology Co Ltd	13		\$0.92	\$0.03	\$0.89	4%	\$2.06	\$0.31	-55.34%	196.77%	53.9M	6,431,662	4.69%	54.9M
ACH	Aluminum Corp. of China Limited ADR Class H	10		\$12.43	-\$0.45	\$12.88	-3%	\$13.45	\$4.60	-7.58%	170.22%	10.9B	248,335	0.00%	157.8M
PSTV	Plus Therapeutics Inc	10		\$2.85	-\$0.15	\$3.00	-5%	\$5.42	\$0.93	-47.42%	206.45%	60.2M	476,694	2.29%	21.1M
ABEO	Abeona Therapeutics Inc	10		\$2.42	-\$0.07	\$2.49	-3%	\$3.79	\$0.99	-36.15%	144.44%	238.4M	14,076,944	4%	98.5M
EZPW	EZCORP Inc	8		\$4.80	-\$0.20	\$5.00	-4%	\$6.84	\$3.41	-29.82%	40.76%	266.9M	483,524	14.69%	52.6M
AEZS	AEterna Zentaris Inc.	8		\$1.17	\$0.05	\$1.12	4%	\$3.62	\$0.29	-67.68%	303.45%	136.0M	9,082,381	4%	116.3M
NAKD	Naked Brand Group Ltd	8		\$1.04	-\$0.10	\$1.14	-9%	\$3.40	\$0.07	-69.41%	1385.71%	495.0M	85,123,713	10.04%	476.0M
AMS	American Shared Hospital Services	7		\$2.80	\$0.16	\$2.64	6.06%	\$3.58	\$1.16	-21.79%	141.38%	16.1M	793,482	0.24%	5.8M

\$ASRT - Assertio is a commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions.

Drug pipeline:

Currently, there is 8 FDA approved drugs:

1. ZORVOLEX® (diclofenac) - This drug is indicated for the management of mild to moderate acute pain and the management of osteoarthritis pain. Diclofenac is a non-steroidal anti-inflammatory drug, also known as an NSAID. The lowest GoodRx price for the most common version of Zorvolex is around \$850.64.
2. ZIPSOR® (diclofenac potassium) - diclofenac potassium is a non-steroidal anti-inflammatory drug, also known as an NSAID. It is used to treat pain, inflammation, and swelling. The lowest GoodRx price for the most common version of Zipsor is around \$475.93.
3. VIVLODEX® (meloxicam) - Meloxicam is a non-steroidal anti-inflammatory drug (NSAID). It is used to reduce swelling and to treat pain, it is used for osteoarthritis. The lowest GoodRx price for the most common version of Vivlodex is around \$1,046.05.

4. SPRIX® (ketorolac tromethamine) - Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). It is used for a short while to treat moderate to severe pain, including pain after surgery. It should not be used for more than 5 days. The lowest GoodRx price for the most common version of generic Sprix is around \$2,217.20
5. OXAYDO® (oxycodone HCl, USP) - Oxycodone is a pain reliever. It is used to treat moderate to severe pain. This is a controlled substance as it's an opioid. The lowest GoodRx price for the most common version of Oxaydo is around \$1,718.68.
6. INDOCIN® (indomethacin) - Indomethacin is a non-steroidal anti-inflammatory drug (NSAID). It is used to reduce swelling and to treat pain. It may be used for painful joint and muscular problems such as arthritis, tendinitis, bursitis, and gout. The lowest GoodRx price for the most common version of generic Indocin is around \$15.34.
7. INDOCIN® Oral Suspension - Same as above
8. Cambia® (diclofenac potassium) - diclofenac potassium is a non-steroidal anti-inflammatory drug, also known as an NSAID. It treats pain, inflammation, and swelling. The lowest GoodRx price for the most common version of generic Cambia is around \$55.64.

According to their website, A next-generation Cambia is in development right now.

Recent News:

1. On Feb 5, ASRT has announced the opening of a DPO of \$14 million dollars, for a Roth Capital Partners to purchase 22,600,000 shares of its stock at a purchase price of \$0.62 per share. The DPO closed on Feb 9th.
2. On Feb 10th, the next day after the first DPO closed, a second DPO was announced of \$34.3 million dollars for Roth Capital Partners to purchase 35,000,000 shares of its common stock at a price of \$0.98 per share. It should be noted that this is a premium to market based on applicable Nasdaq "minimum price" rules. Meaning that a ticker must close above \$1 for 10 consecutive days to be listed on Nasdaq. Currently, ASRT met compliance last week.
3. ASRT will release fourth quarter and full-year 2020 financial results on Thursday, March 11, 2021, after the close of markets.

Market watch rates this stock as overweight with a High of \$3.50 a Median of \$2.13 and a Low of \$0.75. **Wall Street Journal** raised price target to \$3.50

The ticker currently sits at \$0.85.

1. For those that do not know what overweight means, basically, if an analyst rates a stock as “overweight,” they think that the stock will perform well in the future, and believes it is worth buying—it could outperform the broader market and other stocks in its sector.
2. Golden cross speculation:
 - a. As many of you have probably seen, there has been word that ASRT will hit a golden cross soon. I did my own research on this and it’s still a bit too early to call, I’d give it a few more days but this does look promising. Chart below for details:



\$AMC - Not a penny stock.

\$CTXR - Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Product pipeline:

1. Mino-Lok® - Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients

where venous access presents a challenge. In a Phase 2b trial, the Mino-Lok product demonstrated a 100% efficacy rate in salvaging colonized CVCs. FDA Fast Track with QIDP designation and patent protection until June 2024. Formulation patent protection until November 2036. Currently, they are in a phase 3 trial.

2. Halo-Lido - Halobetasol-Lidocaine Formulation (CITI-002)
 - a. Need : There are no FDA-approved prescription products on the market for hemorrhoids.
 - b. Ask : CTXR is developing a proprietary topical formulation of halobetasol and lidocaine to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.
 - c. Yes, there are many over-the-counter (OTC) products commonly used to treat hemorrhoids, just ask anyone's grandma. However, CTXR claims that none of those medications participated in a rigorously-conducted clinical trial to amplify results. Maybe that's why my grandma is still in pain. This could become the first FDA-approved product to treat hemorrhoids in the United States. Could.

3. Mino-Wrap (CITI-101) - This product is designed to reduce infections associated with the use of breast tissue expanders used in breast reconstruction surgeries following mastectomies. For all you men in this sub, a Mastectomy is performed to remove one or both breasts, partially or completely due to breast cancer mainly.
 - a. In January 2019, CTXR signed a definitive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop and commercialize this novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is being reviewed by the FDA's Center for Drug Evaluation and Research division.

News:

1. On Feb 17, CTXR announced a DPO of \$76.5 Million to H.C. Wainwright & Co. 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock,

at a purchase price of \$1.505 per share. The warrants have an exercise price of \$1.70 per share, will be immediately exercisable and will expire five years from the issue date.

2. On Feb 16, CTXR issued a shareholder letter, some highlights include:
 - a. Mino-Lok® pivotal trial interim analysis and review by the Data Monitoring Committee (DMC) expected in the second quarter
 - b. Halo-Lido IND (second quarter) and Phase 2b protocol to be filed afterwards
 - c. Mino-Wrap™ in pre-clinical development with plans to submit IND to the FDA by the end of the year
 - d. NoveCite i-MSCs development is progressing with: ongoing data generation from our proof-of-concept sheep acute respiratory distress syndrome (ARDS) model demonstrating impressive interim results (studies to be completed in second quarter); FDA-required GLP animal toxicology studies have been implemented; and development of an i-MSc master cell bank (MCB) followed by cGMP manufacturing is underway. Private placement for gross proceeds of \$20.0 million and investors' exercise of warrants generating \$4.5 million in gross proceeds completed in January 2021 and February 2021, respectively.
 - e. The walrus likes this stock.
3. Competitor:
 - a. \$CRMD - is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. CRMD is releasing news on they're preventative catheters, looks like tomorrow. If they received FDA approval, think about what may happen to CTXR ticker.

Market watch rates CTXR as a buy with a High, Median and Low price point at \$8.00. The ticker currently sits at \$2.03.

\$SOS - SOS Limited is a high-tech company with AI block chain as the core technology, headquartered in Qingdao, **China**. The company provides customers with rescue, big data, trade, digital asset management and other


information technology services through AI block technology and satellite communication.

1. Product pipeline: The following services are available for users through the tech developed by SOS. Communication for these services are done via satellite communication, network community, app, wechat, telephone.
 - a. Medical rescue services:
 - i. Telephone medical consultation - Daily medical consultations and first aid guidance.
 - ii. Business travel rescue service - If the hospital has no conditions for treatment due to "accidental injury" or "sudden acute disease", arrange rescue tools to transfer the customer to the appropriate medical institution; or return the customer to his habitual residence upon request
 - iii. Funerals, ashes returned, and aftercare
 - iv. Visit to family members of returned minor children - When there are children under the age of 16 who are not cared for, the doctor of the rescue organization will arrange the accompanying children to return to the place of habitual residence according to the needs of the customer.
 - v. Vehicle rescue service: This is part of the overall “ Medical Rescue.” Sounds very similar to AAA.
 1. Connection service
 2. Emergency water filling
 3. Replace the spare wheel
 4. On site emergency repair
 5. Trailer towing
 6. Lifting rescue
 7. Rescue in trouble
 - vi. Financial and Life Rescue services: Respond to the uncertain economic situation that came about from a medical incident. This provides users with emergency rescue services for their finances.
 - b. Information Services: From my understanding, SOS tech helps the following types of phone banks:
 - i. Telecommunications call service
 - ii. Insurance call service

- iii. Bank call service
- c. All the above services have a “rescue card” for users.



- i.
- d. Blockchain:
 - i. See above definition but basically SOS uses block chain for the following (pictured below). Blockchain and privacy computing technology, provides information infrastructure for the digital era, including autonomous controllable alliance blockchain platform, data asset value exchange platform based on multi-party security computing, distributed credit and identity authentication system based on privacy computing, etc. So yes, SOS uses blockchain to mine crypto.



- e. [Medical Apparatus](#) is listed on their website as a product but there is no information on the page.
- f. For more information on products see there website [here](#)
- 2. In the news:
 - a. SOS Announces that the First Batch of 5000 Pieces of Crypto Mining Rigs Gone Live on February 23rd.

- i. This batch of 5000 PCS of mining rigs can generate about BTC Hash Power 175P. If the machine operates as expected, the annual ROI (return on investment) is projected to be significant based on the current crypto price momentum.
 - b. SOS Announces that Receipt of the Second Batch of 5000 Pieces of Crypto Mining Rigs on February 24th.
 - i. The pool of 5000 PCS will be able to generate about BTC Hash Power 175P and ETH Hash Power 350G.
 - c. On February 25th, SOS announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate of 23,880,000 of its American Depositary Shares (“ADSs”) issued by the company on February 10, 2021, at an exercise price of \$4.05. The gross proceeds to the company from the exercise of the warrants are expected to be approximately \$96.7 million, prior to deducting fees and estimated offering expenses.
 - d. On February 25th, SOS announced the Construction of a Hash Power Plant in Hejiang County, Luzhou, Sichuan(Cloud Crypto Mining Center). This is a future catalyst.
3. Market watch and WSJ both rate this stock as a hold with a high, median and low stock price of \$20. The stock is currently \$4.77.

\$AGTC - AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

1. Product pipeline:
 - a. AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia:

	IND ENABLING	PHASE 1/2	PHASE 2/3	NEXT MILESTONE*
Ocular				
XLRP	RPGR (Orphan Drug)			Clinical Data
ACHM	CNGB3 (Orphan Drug)			Clinical Data
	CNGA3 (Orphan Drug)			
Optogenetics	Bionic Sight			Clinical Data
Dry AMD	Complement Factor H			IND Filing
Stargardts	ABCA4			IND Filing
Neurodegenerative				
FTD	Progranulin			IND Filing
ALS	C9ORF72			Development Candidate
Otology				
Non-Syndromic Hearing Loss	gJB2			IND Filing

- i. AGTC is currently conducting two separate Phase 1/2 clinical trials to evaluate the safety and efficacy of AAV gene therapy product candidates in patients with *Achromatopsia* (ACHM) which is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes.
- ii. AGTC is currently conducting phase 1/2 clinical trial of [Bionic Sight](#).
- iii. AGTC is currently in the proof of concept phase for Dry AMD. Age-related Macular Degeneration (AMD) is a medical condition that affects over 24 million people globally. AMD may result in blurred or no vision in the center of the visual field. Loss of central vision can make it hard to recognize faces, read, drive and perform daily activities.
- iv. AGTC is currently in the proof of concept phase for DFNB1. Non-syndromic hearing loss and deafness (DFNB1) is an autosomal recessive disorder characterized by congenital non-progressive mild-to-profound sensorineural hearing impairment. DFNB1 is the most common form of genetic hearing loss, accounting for nearly 30% of all cases.
- v. AGTC is currently in the phase 2 expansion phase for XLRP. Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time.

From the most recent press release: "As of December 31, 2020, the Company's cash, cash equivalents and investments totaled \$53.1 million. The Company believes that these funds, along with net proceeds of approximately \$69.2 million from an underwritten public offering that closed in February 2021, will be sufficient to allow the Company to generate data from its ongoing and planned clinical programs and fund currently planned research and discovery programs into calendar year 2023."

Market watch rates this stock as a buy with a high stock price target of \$35, a median of \$12.00 and a low of \$9.00. Currently, it sits at \$5.08.

Another thesis completed! Thanks everyone for your support.